Merck & MMR Vaccine

Merck Accused of Lying about Vaccine Effectiveness

July 10 2012

Story at-a-glance

  • Two virologists have filed a federal lawsuit against Merck, their former employer, alleging the vaccine maker overstated the effectiveness of their mumps vaccine, which may have cost the US government hundreds of millions of dollars over the past decade. They claim they “witnessed firsthand the improper testing and data falsification in which Merck engaged to artificially inflate the vaccine’s efficacy findings”
  • Chatom Primary Care has also filed a federal antitrust class action lawsuit against Merck, alleging Merck went to great lengths to manipulate test procedures and falsifying results to prop up fraudulent efficacy claims, thereby maintaining its monopoly on the MMR vaccine
  • These two lawsuits couldn’t come at a more precarious time for Merck, as the Italian Health Ministry recently conceded the MMR vaccine caused autism in a now nine-year old boy—albeit this news has been effectively censored in the US
  • A recent review of the varicella (chickenpox) vaccination program in the U.S. concluded that the vaccine has not proven to be cost-effective; increased the incidence of shingles; failed to provide long-term protection from the disease it targets―chicken pox―and; is less effective than the natural immunity that existed in the general population before the vaccine. Vaccine efficacy was found to have declined well below 80 percent by of 2002

By Dr. Mercola

Things aren’t going so well lately in the litigation department for Merck, which stands accused of lying according to not just one, but two class-action lawsuits.

In the first case, two former Merck virologists accuse their former employer of overstating the effectiveness of the mumps vaccine in Merck’s combination MMR shot, which may have cost the US government hundreds of millions of dollars over the past decadei.

Merck’s mumps vaccine was originally licensed 45 years ago. Since the 1970s, it’s been part of the trivalent measles, mumps and rubella (MMR) vaccine, which is part of the recommended childhood vaccination schedule. The case, which was initially filed in 2010, was unsealed late last month. As reported by the Courthouse News Serviceii:

“… Stephen Krahling and Joan Wlochowski were Merck virologists who claim in their unsealed complaint that they “witnessed firsthand the improper testing and data falsification in which Merck engaged to artificially inflate the vaccine’s efficacy findings.”

… As the largest single purchaser of childhood vaccines (accounting for more than 50 percent of all vaccine purchases), the United States is by far the largest financial victim of Merck’s fraud,” according to the 2010 False Claims Act complaint.”

According to Nasdaq.comiii:

“Merck–which stressed that none of these allegations relate to the safety of its product–said the lawsuit is “completely without merit”, and that it plans to “vigorously defend itself.”

It’s quite interesting to note the chosen language in Merck’s rebuttal. It in no way addresses the issue of the vaccine’s effectiveness, which is the core issue of the lawsuit and the allegation by the two former Merck employees that the drug company purposefully used improper testing methods and falsified data to make the mumps vaccine appear highly effective when the opposite was true. Instead, Merck responds by saying that none of the lawsuit’s allegations relate to the safety of its products. Such evasive maneuvering certainly gives the appearance of an admission of guilt.

Second Lawsuit Filed

A mere week after the first case was unsealed, a federal antitrust class action lawsuit was filed by Chatom Primary Care. According to Courthouse News Serviceiv:

“Merck has known for a decade that its mumps vaccine is “far less effective” than it tells the government, and it falsified test results and sold millions of doses of “questionable efficacy,” flooding and monopolizing the market, a primary caregiver claims in a federal antitrust class action.

… Chatom says in its antitrust complaint that Merck falsely claims its mumps vaccine is 95 percent effective. That claim “deterred and excluded competing manufacturers,” who would enter the risky and expensive vaccine market only if they believed they could craft a better product…

Merck is the only manufacturer licensed by the FDA to sell the mumps vaccine in United States, and if it could not show that the vaccine was 95 percent effective, it risked losing its lucrative monopoly… That’s why Merck found it critically important to keep claiming such a high efficacy rate, the complaint states. And, Chatom claims, that’s why Merck went to great lengths, including “manipulating its test procedures and falsifying the test results,” to prop up the bogus figure, though it knew that the attenuated virus from which it created the vaccine had been altered over the years during the manufacturing process, and that the quality of the vaccine had degraded as a result.”

According to these two lawsuits, Merck began a sham testing program in the late 1990’s to hide the declining efficacy of the vaccine. The objective of the fraudulent trials was to “report efficacy of 95 percent or higher regardless of the vaccine’s true efficacy.” This program was initially referred to as “Protocol 007,” the Chatom claim states, and instead of testing the vaccine’s efficacy against a wild mumps virus, as is the norm, Merck used its own attenuated strain of the virus—the identical strain with which the children were being vaccinated!

That’s as brilliant as it is devious, and a perfect example of how medical research can be manipulated to achieve desired results. Suzanne Humphries recently wrote an excellent summary for GreenMedInfo.com, explaining in layman’s terms how the tests were manipulated (see Sources). The two virologists bringing the lawsuit against Merck claim they witnessed firsthand this deception and were asked to directly participate in it.

As reported by the Courthouse News Servicev:

“That “subverted” the purpose of the testing regime, “which was to measure the vaccine’s ability to provide protection against a disease-causing mumps virus that a child would actually face in real life. The end result of this deviation … was that Merck’s test overstated the vaccine’s effectiveness,” Chatom claims.

Merck also added animal antibodies to blood samples to achieve more favorable test results, though it knew that the human immune system would never produce such antibodies, and that the antibodies created a laboratory testing scenario that “did not in any way correspond to, correlate with, or represent real life … virus neutralization in vaccinated people,” according to the complaint.

Chatom claims that the falsification of test results occurred “with the knowledge, authority and approval of Merck’s senior management.”

Health versus Profits

Considering the extent of the allegations here, it is really shocking that the conventional media has not picked up on this story. About the only major media source reporting on it was Forbes Magazinevi

to read more and see the video, go to:    http://articles.mercola.com/sites/articles/archive/2012/07/10/merck-lying-about-vaccine-effectiveness.aspx?e_cid=20120710_DNL_artNew_1